1. Home
  2. LYB vs ILMN Comparison

LYB vs ILMN Comparison

Compare LYB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LyondellBasell Industries NV (Netherlands)

LYB

LyondellBasell Industries NV (Netherlands)

HOLD

Current Price

$63.13

Market Cap

25.9B

Sector

Industrials

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$159.49

Market Cap

24.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYB
ILMN
Founded
1955
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.9B
24.6B
IPO Year
2010
2000

Fundamental Metrics

Financial Performance
Metric
LYB
ILMN
Price
$63.13
$159.49
Analyst Decision
Hold
Hold
Analyst Count
17
17
Target Price
$69.35
$124.24
AVG Volume (30 Days)
3.9M
1.8M
Earning Date
05-01-2026
04-30-2026
Dividend Yield
3.77%
N/A
EPS Growth
N/A
170.87
EPS
0.38
0.87
Revenue
$30,153,000,000.00
$4,343,000,000.00
Revenue This Year
$5.55
$6.47
Revenue Next Year
N/A
$5.58
P/E Ratio
$169.55
$181.67
Revenue Growth
N/A
N/A
52 Week Low
$41.58
$85.77
52 Week High
$83.94
$177.22

Technical Indicators

Market Signals
Indicator
LYB
ILMN
Relative Strength Index (RSI) 29.59 60.95
Support Level $42.06 $116.54
Resistance Level $78.43 N/A
Average True Range (ATR) 2.03 6.79
MACD -0.61 0.17
Stochastic Oscillator 9.52 54.69

Price Performance

Historical Comparison
LYB
ILMN

About LYB LyondellBasell Industries NV (Netherlands)

LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: